NasdaqGS:EWTX
NasdaqGS:EWTXPharmaceuticals

Will Edgewise Therapeutics’ (EWTX) Rising Losses Reshape Its Long-Term Investment Strategy?

Edgewise Therapeutics, Inc. reported its second quarter and six-month earnings for the period ended June 30, 2025, disclosing a net loss of US$36.12 million for the quarter and US$76.91 million for the half-year, both increases from the same periods last year. Although the company's per-share loss for the quarter remained flat at US$0.34, overall losses grew year-over-year reflecting rising expenses or investment activity. Given the rise in net loss while per-share loss stayed unchanged,...
NasdaqCM:LMB
NasdaqCM:LMBConstruction

Will Raised Revenue Guidance and Margin Focus Change Limbach Holdings' (LMB) Long-Term Earnings Narrative?

Earlier this month, Limbach Holdings, Inc. raised its 2025 full-year revenue guidance to a range of US$650 million–US$680 million and reported second-quarter sales of US$142.24 million, up from US$122.24 million a year prior, alongside a higher net income of US$7.76 million. This combination of improved financial outlook and year-over-year profit growth signals operational momentum as the company focuses on higher-margin recurring service contracts. We’ll examine how the updated revenue...
NasdaqGS:DMLP
NasdaqGS:DMLPOil and Gas

How Investors May Respond To Dorchester Minerals (DMLP) Rising Sales With Sliding Profit Margins

Dorchester Minerals, L.P. recently reported its second quarter and six-month earnings, revealing second quarter revenues of US$32.4 million and net income of US$11.91 million, both down from the same period last year, despite a substantial increase in sales. Interestingly, six-month revenue rose to US$75.56 million compared to the previous year, though net income declined, highlighting shifting profitability trends amid growing sales. We'll explore how the combination of rising sales and...
NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

How Lower Guidance and New FDA Progress Will Impact Lantheus Holdings (LNTH) Investors

In August 2025, Lantheus Holdings announced lower financial guidance for the year, reported a sales decline for the second quarter versus the previous year, and disclosed FDA acceptance of a new drug application for its F 18 PSMA imaging agent. Alongside earnings updates, the company unveiled a US$400 million share repurchase program and highlighted plans to expand patient access through a more efficient formulation of its leading PSMA imaging product. We will examine how the reduced...
NasdaqGS:SAFT
NasdaqGS:SAFTInsurance

Should Robust Earnings and a Dividend Hike at Safety Insurance Group (SAFT) Prompt Investor Action?

Safety Insurance Group announced second quarter 2025 results, reporting revenue of US$316.34 million and net income of US$28.94 million, both showing significant increases from the previous year, along with an increase in its quarterly dividend to US$0.92 per share payable in September 2025. This combination of robust earnings growth and a higher dividend payout underscores the company's focus on delivering consistent value to shareholders. We'll explore how the newly increased dividend...